Supernus reports 39% Q1 revenue growth to $207.7M, driven by ZURZUVAE and ONAPGO

Filed May 5, 2026 · Period ending May 5, 2026 · ~1 min read

Key Changes

• high

  Q1 2026 revenues rose 39% year-over-year to $207.7M, driven by 56% growth in four key products (Qelbree, GOCOVRI, ZURZUVAE, ONAPGO) to $149.1M and a $20M Shionogi commercial milestone.

  Item 2.02 — Results of Operations and Financial Condition verify on EDGAR →
• high

  ZURZUVAE collaboration revenue reached $27.6M (50% of Biogen's net revenues); Biogen reported U.S. sales doubled year-over-year and total prescriptions increased 82%.

  Exhibit 99.1 verify on EDGAR →
• high

  Company reaffirmed full-year 2026 guidance: $840-870M total revenues, $0-30M operating earnings, and $140-170M adjusted operating earnings.

  Exhibit 99.1 verify on EDGAR →